

# Richard G Moore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/286253/publications.pdf>

Version: 2024-02-01

53  
papers

3,653  
citations

257450

24  
h-index

182427

51  
g-index

53  
all docs

53  
docs citations

53  
times ranked

3521  
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. <i>Gynecologic Oncology</i> , 2009, 112, 40-46.	1.4	702
2	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. <i>Gynecologic Oncology</i> , 2008, 108, 402-408.	1.4	594
3	Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass. <i>Obstetrics and Gynecology</i> , 2011, 118, 280-288.	2.4	224
4	Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 228.e1-228.e6.	1.3	219
5	Incidence of metastasis to the ovaries from nongenital tract primary tumors. <i>Gynecologic Oncology</i> , 2004, 93, 87-91.	1.4	188
6	Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. <i>Gynecologic Oncology</i> , 2013, 129, 277-284.	1.4	185
7	Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. <i>Gynecologic Oncology</i> , 2008, 110, 196-201.	1.4	184
8	Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 349.e1-349.e7.	1.3	117
9	Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 351.e1-351.e8.	1.3	116
10	Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva. <i>Gynecologic Oncology</i> , 2003, 89, 475-479.	1.4	96
11	Current state of biomarker development for clinical application in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 240-245.	1.4	92
12	HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. <i>Scientific Reports</i> , 2014, 4, 3574.	3.3	79
13	Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. <i>Gynecologic Oncology</i> , 2003, 91, 378-382.	1.4	68
14	Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: A prospective trial. <i>Gynecologic Oncology</i> , 2008, 109, 65-70.	1.4	62
15	The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. <i>International Journal of Oncology</i> , 2015, 46, 1924-1934.	3.3	62
16	Utility of Tumor Marker HE4 to Predict Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of the Uterus. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	2.5	58
17	Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone. <i>Gynecologic Oncology</i> , 2014, 133, 416-420.	1.4	48
18	A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 6003-6003.	1.6	42

#	ARTICLE	IF	CITATIONS
19	Current clinical use of biomarkers for epithelial ovarian cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 492-497.	2.4	41
20	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2138-2147.	1.6	40
21	Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1 $\alpha$ in cancer cells. <i>Scientific Reports</i> , 2015, 5, 14296.	3.3	38
22	Vulvar Epithelioid Sarcoma in Pregnancy. <i>Gynecologic Oncology</i> , 2002, 85, 218-222.	1.4	34
23	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	32
24	Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw251.	6.3	28
25	Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?. <i>Gynecologic Oncology</i> , 2019, 154, 150-155.	1.4	25
26	Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial. <i>Gynecologic Oncology</i> , 2015, 139, 70-76.	1.4	23
27	Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracellular Matrix. <i>Frontiers in Oncology</i> , 2017, 7, 332.	2.8	23
28	Predictive factors for the presence of malignant transformation of pelvic endometriosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 185, 23-27.	1.1	22
29	Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. <i>Gynecologic Oncology</i> , 2022, 166, 36-43.	1.4	18
30	A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 68.e1-68.e8.	1.3	17
31	The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes. <i>Scientific Reports</i> , 2020, 10, 8558.	3.3	16
32	Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model. <i>PLoS ONE</i> , 2012, 7, e34443.	2.5	16
33	Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers. <i>Scientific Reports</i> , 2015, 5, 15911.	3.3	14
34	Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer. <i>Journal of Robotic Surgery</i> , 2018, 12, 245-250.	1.8	13
35	HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression. <i>Journal of Immunology</i> , 2021, 206, 2478-2488.	0.8	13
36	Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 547-551.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Receipt of adjuvant endometrial cancer treatment according to race: anÂNRG Oncology/Gynecologic Oncology Group 210 Study. American Journal of Obstetrics and Gynecology, 2018, 219, 459.e1-459.e11.	1.3	12
38	PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. Genes and Cancer, 2013, 4, 524-534.	1.9	11
39	Predictors for lymph nodes involvement in low risk endometrial cancer. Journal of Obstetrics and Gynaecology, 2017, 37, 514-518.	0.9	8
40	Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins. Oncotarget, 2019, 10, 2959-2972.	1.8	8
41	Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer. Translational Oncology, 2019, 12, 917-924.	3.7	7
42	Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6. Frontiers in Pharmacology, 2019, 10, 216.	3.5	7
43	A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical Cancer Research, 2021, 27, 2734-2741.	7.0	7
44	Antitumor Activity of 3-Indolylmethanamines 31B and PS121912. Anticancer Research, 2015, 35, 6001-7.	1.1	7
45	Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass. Cancers, 2022, 14, 1291.	3.7	7
46	Assessment of serum HE4 levels throughout the normal menstrual cycle. American Journal of Obstetrics and Gynecology, 2017, 217, 53.e1-53.e9.	1.3	6
47	Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumor Biology, 2021, 43, 355-365.	1.8	4
48	Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors <i>In Vivo</i> . Journal of Medicinal Chemistry, 2022, 65, 6039-6055.	6.4	3
49	Evaluation and Management of Women Presenting with a Pelvic Mass. Current Obstetrics and Gynecology Reports, 2012, 1, 10-15.	0.8	2
50	Templated polymers enable selective capture and release of lysophosphatidic acid in human plasma via optimization of non-covalent binding to functional monomers. Analyst, The, 2015, 140, 7572-7577.	3.5	2
51	Evolution and Transformation of Uterine Transplantation: A Systematic Review of Surgical Techniques and Outcomes. Journal of Reconstructive Microsurgery, 2022, 38, 429-440.	1.8	1
52	HE4 Promotes Events Associated with Metastatic Ovarian Cancer Via Regulation of the Extracellular Matrix. FASEB Journal, 2018, 32, 804.1.	0.5	0
53	Biomarker lead time for predicting progression in women with ovarian cancer compared to imaging.. Journal of Clinical Oncology, 2020, 38, e18074-e18074.	1.6	0